CN101175508A - 表皮葡萄球菌多肽抗原的免疫原性组合物 - Google Patents

表皮葡萄球菌多肽抗原的免疫原性组合物 Download PDF

Info

Publication number
CN101175508A
CN101175508A CNA2005800360186A CN200580036018A CN101175508A CN 101175508 A CN101175508 A CN 101175508A CN A2005800360186 A CNA2005800360186 A CN A2005800360186A CN 200580036018 A CN200580036018 A CN 200580036018A CN 101175508 A CN101175508 A CN 101175508A
Authority
CN
China
Prior art keywords
seq
leu
glu
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800360186A
Other languages
English (en)
Chinese (zh)
Inventor
布雷特·理查德·塞尔曼
史蒂文·莫里斯·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101175508A publication Critical patent/CN101175508A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2005800360186A 2004-10-21 2005-10-19 表皮葡萄球菌多肽抗原的免疫原性组合物 Pending CN101175508A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62078804P 2004-10-21 2004-10-21
US60/620,788 2004-10-21

Publications (1)

Publication Number Publication Date
CN101175508A true CN101175508A (zh) 2008-05-07

Family

ID=37595601

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800360186A Pending CN101175508A (zh) 2004-10-21 2005-10-19 表皮葡萄球菌多肽抗原的免疫原性组合物

Country Status (13)

Country Link
US (3) US8445000B2 (https=)
EP (4) EP2298341A3 (https=)
JP (2) JP2008517918A (https=)
KR (1) KR20070068455A (https=)
CN (1) CN101175508A (https=)
AR (1) AR051826A1 (https=)
AU (1) AU2005333603A1 (https=)
BR (1) BRPI0516974A (https=)
CA (1) CA2583121A1 (https=)
IL (1) IL182546A0 (https=)
TW (1) TW200619228A (https=)
WO (1) WO2007001423A2 (https=)
ZA (1) ZA200703274B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102647999A (zh) * 2009-04-14 2012-08-22 诺华有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN109843910A (zh) * 2016-10-21 2019-06-04 索克普拉科学与工程公司 对抗葡萄球菌感染的疫苗构建体及其用途
CN112521464A (zh) * 2014-03-26 2021-03-19 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
US20110200995A1 (en) * 2009-09-04 2011-08-18 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of vancomycin resistance genes and vancomycin resistant enterococci
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
WO2020159758A1 (en) * 2019-01-30 2020-08-06 Fujifilm Electronic Materials U.S.A., Inc. Container and method of preparing the same
KR102627009B1 (ko) * 2021-12-17 2024-01-19 (주)메디톡스 피부 유해 세균에 대한 항세균 활성을 갖는 세균 균주, 및 이를 포함하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
ES2198405T3 (es) * 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
CA2132421C (en) 1992-03-19 2010-11-23 Gerald W. Fischer Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
HU219767B (hu) 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT783520E (pt) * 1994-09-21 2002-05-31 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
JP4714342B2 (ja) 1998-08-31 2011-06-29 ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE542829T1 (de) 2001-08-02 2012-02-15 Univ Sheffield Impfstoff
PL229487B1 (pl) * 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2007523609A (ja) * 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト 表皮ブドウ球菌抗原
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
JP5171611B2 (ja) 2005-03-25 2013-03-27 ナショナル リサーチ カウンシル オブ カナダ 可溶性ポリペプチドの単離方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102647999A (zh) * 2009-04-14 2012-08-22 诺华有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN112521464A (zh) * 2014-03-26 2021-03-19 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
CN109843910A (zh) * 2016-10-21 2019-06-04 索克普拉科学与工程公司 对抗葡萄球菌感染的疫苗构建体及其用途

Also Published As

Publication number Publication date
CA2583121A1 (en) 2007-01-04
AR051826A1 (es) 2007-02-14
JP2008517918A (ja) 2008-05-29
TW200619228A (en) 2006-06-16
ZA200703274B (en) 2008-06-25
EP2213298A2 (en) 2010-08-04
US8445000B2 (en) 2013-05-21
AU2005333603A1 (en) 2007-01-04
JP2013121981A (ja) 2013-06-20
EP2298341A3 (en) 2011-07-13
EP2298341A2 (en) 2011-03-23
IL182546A0 (en) 2008-12-29
WO2007001423A2 (en) 2007-01-04
US20130209501A1 (en) 2013-08-15
KR20070068455A (ko) 2007-06-29
US20070292450A1 (en) 2007-12-20
EP2340848A3 (en) 2011-09-14
EP1802335A2 (en) 2007-07-04
WO2007001423A3 (en) 2007-11-15
BRPI0516974A (pt) 2008-09-30
US20150196629A1 (en) 2015-07-16
EP2213298A3 (en) 2011-07-20
EP2340848A2 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
KR101359930B1 (ko) 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물
KR101541383B1 (ko) 면역원성 조성물
KR100886095B1 (ko) 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
US20130209501A1 (en) Immunogenic Compositions of Staphylococcus Epidermidis Polypeptide Antigens
WO1997043303A1 (en) Novel compounds
KR20200057757A (ko) 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
KR20150056540A (ko) 백신으로서의 클로스트리듐 디피실 폴리펩티드
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
US6777547B1 (en) Collagen-binding proteins from streptococcus pyogenes
US20040219585A1 (en) Nontypeable haemophilus influenzae virulence factors
JP2000512485A (ja) 新規化合物
HK1117077A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
JP2000509984A (ja) 新規化合物
RU2773917C2 (ru) Композиции и способы для вызывания иммунного ответа против clostridium difficile
CA2396674C (en) Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein
JP2000510335A (ja) 新規化合物
MX2007004834A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
AU2002220422A1 (en) S.aureus protein STAAU R2, gene encoding it and uses thereof
WO2002044718A2 (en) S.aureus protein staau r2, gene encoding it and uses thereof
US20040137516A1 (en) DNA sequences from staphylococcus aureus bacteriophage 44AHJD that encode anti-microbial polypeptides
JP2002506624A (ja) スタフィロコッカス・アウレウスｓｐｏ０ｊ２：ポリヌクレオチドおよび蛋白
JP2000102385A (ja) ｄｅｆ１

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117077

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080507

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1117077

Country of ref document: HK